A randomized phase II trial of gemcitabine, nab‐paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer

Q: What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 2).

Gayle Jameson; Denise J. Roe; Erkut Borazanci; Diana L. Hanna; Caroline G. P. Roberts; Meredith S. Pelster; Richard C. Frank; Angela Alistar; Alan M. Miller; J. Erin Wiedmeier‐Nutor; Sandra D. Algaze; Alison R. Zoller; Sarah J. Hallberg; Betsy C. Wertheim; Keehoon Lee; Derek Cridebring; Joshua D. Rabinowitz; Stephen Gately; Jennifer Keppler; Sunil Sharma; Daniel D. Von Hoff; Drew Rasco

doi:10.1002/cncr.70343

Key Points

To evaluate the feasibility of a medically supervised ketogenic diet alongside chemotherapy in patients with metastatic pancreatic cancer.
Compared outcomes of chemotherapy with and without the ketogenic diet.
Measured progression-free survival (PFS), overall survival (OS), toxicity, and quality of life (QOL).
Showed trends towards improved PFS and OS for those receiving the ketogenic diet and chemotherapy.
No added toxicity was observed from the combined treatment.
Quality of life (QOL) remained unaffected.

Implication

Shows trends in improved survival in metastatic pancreatic cancer, indicating potential for ketogenic diet with chemotherapy.

Abstract

The MSKD is feasible in patients with PDAC and, although not powered for definitive outcomes, shows trends in improved PFS and OS when combined with gemcitabine, nab-paclitaxel, and cisplatin, without added toxicity or detriment to QOL. Larger studies are required to confirm these findings and establish the value of the MSKD in pancreatic cancer treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Jameson et al. (2026) studied this question.

synapsesocial.com/papers/69b4ad8d18185d8a39800f2f https://doi.org/10.1002/cncr.70343

View Full Paper

Ask AI

Bookmark

Share

A randomized phase II trial of gemcitabine, nab‐paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

A randomized phase II trial of gemcitabine, nab‐paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading